Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
De-etiolated-1 homolog (DET1) is a nuclear chromatin-binding protein functioning as a key substrate adaptor in multi-protein E3 ubiquitin ligase complexes that contain CUL4, DDB1, DDA1, and COP1. DET1 specifically recruits certain E2 enzymes and the COP1 E3 ligase, coordinating the polyubiquitination and subsequent proteasomal degradation of various transcription factors involved in key biological processes such as immune, metabolic, and neurodevelopmental regulation. DET1's structural dynamics, modulated by protein-protein interactions and post-translational modifications, govern its ability to assemble complexes that regulate cell fate and environmental response. Although critical in developmental programming and disease progression, DET1 is not currently a direct therapeutic target; rather, its modulatory role in transcription factor stability makes it a node of biological interest in cancer, neurodevelopment, and possibly resistance phenomena.
Not applicable (DET1 is not currently targeted directly by drugs; it acts as a substrate adaptor and regulator in ubiquitin ligase complexes)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on De-etiolated-1 homolog (DET1).